Search

Displaying results 1711 - 1720 of 5895 in total
  1. Drug

    Atrasentan

    go.drugbank.com/drugs/DB06199
    ApprovedInvestigational

    In April 2025, atrasentan was granted accelerated approval by the FDA for the reduction of proteinuria in patients with primary IgA nephropathy, becoming the first endothelin A receptor antagonist to

  2. Drug

    Ambroxol

    go.drugbank.com/drugs/DB06742
    ApprovedInvestigational

    Surfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.

    Products: AMBROXOLO MYLAN GENERICS
  3. Drug

    Thiotepa

    go.drugbank.com/drugs/DB04572
    ApprovedInvestigational

    It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

  4. Drug

    Xenon-133

    go.drugbank.com/drugs/DB09315
    Approved

    Xenon-133 is an inhaled radionuclide used for lung imaging, imaging blood flow in the brain, and to assess pulmonary function.

  5. Drug

    Arimoclomol

    go.drugbank.com/drugs/DB05025
    Approved

    Arimoclomol is a hydroxylamine derivative [A264414] and a heat-shock protein-70 (HSP70) co-inducer.

  6. Drug

    Plasminogen

    go.drugbank.com/drugs/DB16701
    ApprovedInvestigational

    [A236035] This pathway is activated when a clot is no longer needed or to prevent a clot from extending beyond the site of injury. … Plasminogen is a pro-enzyme (i.e. a zymogen) which is cleaved to form plasmin - also known as [fibrinolysin] - as part of the fibrinolytic pathway that breaks down fibrin blood clots.

  7. Drug

    Dimetacrine

    go.drugbank.com/drugs/DB08996
    ApprovedWithdrawn

    Dimetacrine is no longer used in Japan.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  8. Drug

    Iberdomide

    go.drugbank.com/drugs/DB12101
    Investigational

    at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. … [L64055] Iberdomide has shown anti-tumor activity in multiple myeloma cells resistant to lenalidomide and pomalidomide, and as a CELMoD is designed to degrade Ikaros and Aiolos more potently than immunomodulatory

  9. Drug

    Linzagolix

    go.drugbank.com/drugs/DB17083
    ApprovedInvestigational

    [A253642,A253647] It is similar to other GnRH receptor antagonists like [cetrorelix], [relugolix], and [elagolix]. … [A253662] As these fibroids are essentially estrogen-dependent phenomena, hormone therapies which suppress estrogen activity - including GnRH receptor antagonists like linzagolix - are thought to be beneficial

  10. Drug

    Linopristin

    go.drugbank.com/drugs/DB19296
    Experimental

    It is one part of the combination product NXL 103, along with [Virginiamycin M1].